Business Context and Reporting Period
This Form 8-K filing by Milestone Scientific Inc. (MLSS) reports corporate actions taken on April 30, 2026. The company, incorporated in Delaware and trading on NYSE American, announced two significant equity compensation initiatives approved by its Compensation Committee: a stock option exchange program for specific executives and the establishment of a new performance-based restricted stock unit (PRSU) sub-plan.
Key Financial Metrics and Equity Actions
The filing does not report standard financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it details specific equity transactions:
- Stock Option Repricing: Outstanding options held by CEO Eric Hines and SVP Jason Papes were repriced from exercise prices of $0.46–$0.50 to $0.31 per share (the closing price on April 30, 2026).
- Repriced Option Volume: A total of 4.0 million shares were subject to the repriced options (2.0 million shares per executive).
- PRSU Sub-Plan Pool: A total aggregate pool of 17,234,635 shares was established for performance milestones, subject to stockholder approval.
- Initial PRSU Grants: 11,202,513 shares were initially awarded to three officers pending stockholder approval.
Material Changes and Program Details
The filing outlines material changes to existing compensation structures and the creation of new incentive frameworks:
- Option Vesting Acceleration: For the repriced options, the vesting schedule was modified. The initial vesting tranche increased from 200,000 to 500,000 shares (25% of the total), with the remainder vesting in two equal tranches over the first and second anniversaries, rather than over three years.
- Performance Milestones: The new PRSU sub-plan ties equity issuance to four-year performance goals (Jan 1, 2026 – Dec 31, 2029), including:
- Organic net sales growth targets exceeding $11.0M, $13.0M, and $15.0M.
- Achievement of a $50 million market capitalization.
- Consummation of a "Qualified Acquisition" with over $10 million in revenue.
- Executive Allocation:
- Eric Hines (CEO): 5,170,391 shares (30% of the initial grant pool).
- Keisha Harcum (VP Finance): 3,016,061 shares (17.5%).
- Jason Papes (SVP Sales/Marketing): 3,016,061 shares (17.5%).
Guidance, Risks, and Contingencies
Management Commentary: The Compensation Committee stated that the repricing was necessary because the original options had diminished retention value due to the stock price falling below the exercise price. The goal is to align executive incentives with stockholder interests without incurring significant cash expenditures or additional dilution beyond the existing option pool.
Contingencies and Risks:
- Stockholder Approval: The PRSU sub-plan and the associated increase in the 2020 Equity Incentive Plan share pool are contingent upon stockholder approval.
- Forfeiture Clauses: Awards are subject to forfeiture if employment terminates prior to milestone achievement, except in cases of termination without cause after a milestone is achieved. Termination for "cause" or breach of restrictive covenants results in immediate forfeiture of all awards, including vested portions.
- Change in Control: In the event of a Change in Control, unachieved milestones are cancelled, though achieved milestones vest. Market cap milestones are valued based on the transaction's imputed value.
Investor Verification Checklist
- Verify the outcome of the upcoming stockholder vote required to approve the PRSU sub-plan and the amendment to the 2020 Equity Incentive Plan.
- Confirm the current trading price of MLSS relative to the $0.31 repriced exercise price to assess the immediate intrinsic value of the new options.
- Monitor the company's progress toward the specific organic sales targets ($11M, $13M, $15M) and the $50 million market capitalization threshold over the 2026-2029 performance period.
- Review the "Qualified Acquisition" definition and any future M&A announcements to determine if the 15% PRSU sub-pool is at risk or likely to be triggered.
- Check for any subsequent filings regarding the actual number of shares issued upon the settlement of the initial PRSU grants.